Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium

Authors Donald P Tashkin

Published 18 February 2010 Volume 2010:5 Pages 41—53

DOI https://doi.org/10.2147/COPD.S9443

Review by Single-blind

Peer reviewer comments 3

Donald P Tashkin

Department of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA,Los Angeles, CA, USA

Abstract: The course of COPD is punctuated by acute exacerbations that are associated with an increase in the morbidity and mortality related to this chronic disease and may contribute to its rate of progression. Therefore, preventing and treating exacerbations are major goals of COPD management. The role of tiotropium in the prevention of exacerbations has been investigated in several placebo-controlled randomized clinical trials varying in duration from 3 months to 4 years in patients with moderate to very severe COPD. In all of these trials, tiotropium has uniformly reduced the proportion of patients experiencing at least one exacerbation and delayed the time to the first exacerbation compared with placebo. In the longer trials (≥6 months’ duration) tiotropium has also reduced the exposure-adjusted incidence rate of exacerbations. In trials of at least 1 year in duration, tiotropium either significantly reduced the risk of hospitalization for an exacerbation and/or the proportion of patients with an exacerbation-related hospitalization. In a meta-analysis that included 15 trials of tiotropium vs either placebo (n = 13) and/or a longacting beta-agonist (LABA; n = 4), tiotropium significantly reduced the odds of experiencing an exacerbation compared to placebo as well as a LABA. The potential additive benefits of tiotropium to those of a LABA and/or inhaled corticosteroid in reducing exacerbations require further investigation. The mechanism whereby tiotropium reduces exacerbations is not due to an anti-inflammatory effect but more likely relates to its property of causing a sustained increase in airway patency and reduction in hyperinflation, thereby counteracting the tendency for respiratory insults to worsen airflow obstruction and hyperinflation. For the management of acute exacerbations, an increase in short-acting inhaled bronchodilators is recommended as needed, while the potential role of long-acting bronchodilators, such as tiotropium, in conjunction with short-acting agents, is unclear and warrants further study.
Keywords: exacerbations, COPD, tiotropium, hospitalization, cardiovascular safety

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Readers of this article also read:

Optimizing management of chronic obstructive pulmonary disease in the upcoming decade

Richard Russell, Antonio Anzueto, Idelle Weisman

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:47-61

Published Date: 10 January 2011

Improving adherence with inhaler therapy in COPD

Suzanne C Lareau, Barbara P Yawn

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:401-406

Published Date: 24 November 2010

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease

Heike Rau-Berger, Harald Mitfessel, Thomas Glaab

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:367-373

Published Date: 10 October 2010

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone

Beatrix Balint, Henrik Watz, Carolynn Amos, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:311-318

Published Date: 6 September 2010

Potential role of stem cells in management of COPD

Tillie L Hackett, Darryl A Knight, Don D Sin

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:81-88

Published Date: 26 March 2010

Tiotropium HandiHaler® in the treatment of COPD: A safety review

Steven Kesten, Bart Celli, Marc Decramer, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:397-409

Published Date: 28 October 2009